Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, et al.
Journal of the National Comprehensive Cancer Network (2020) Vol. 18, Iss. 6, pp. 755-781
Open Access | Times Cited: 130

Showing 1-25 of 130 citing articles:

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Philippe Armand, Margaret A. Shipp, Vincent Ribrag, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 31, pp. 3733-3739
Open Access | Times Cited: 644
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
David J. Straus, Monika Długosz‐Danecka, Joseph M. Connors, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 6, pp. e410-e421
Closed Access | Times Cited: 131
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma
Pamela B. Allen, Hatice Savas, Andrew M. Evens, et al.
Blood (2020) Vol. 137, Iss. 10, pp. 1318-1326
Open Access | Times Cited: 122
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma
Locke J. Bryan, Carla Casulo, Pamela B. Allen, et al.
JAMA Oncology (2023) Vol. 9, Iss. 5, pp. 683-683
Closed Access | Times Cited: 37
Socioeconomic, Race-Ethnicity, Household, and Infrastructure Disparities of Hematologic Cancer Outcomes in the US
David J. Fei‐Zhang, Erik Wu, Alexander Stanisic, et al.
Blood Advances (2025)
Open Access | Times Cited: 1
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
Yang Liu, Chunmeng Wang, Xiang Li, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 4, pp. e002347-e002347
Open Access | Times Cited: 50
Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
Jesko Momotow, Sven Borchmann, Dennis A. Eichenauer, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 5, pp. 1125-1125
Open Access | Times Cited: 49
Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances
Faryal Munir, Viney Hardit, Irtiza Sheikh, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10095-10095
Open Access | Times Cited: 21
International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology
Patrick Veit‐Haibach, Håkan Åhlström, Ronald Boellaard, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 12, pp. 3513-3537
Open Access | Times Cited: 21
The Silva Pattern-based Classification for HPV-associated Invasive Endocervical Adenocarcinoma and the Distinction Between In Situ and Invasive Adenocarcinoma: Relevant Issues and Recommendations From the International Society of Gynecological Pathologists
Isabel Alvarado‐Cabrero, Carlos Parra‐Herran, Simona Stolnicu, et al.
International Journal of Gynecological Pathology (2021) Vol. 40, Iss. Supplement 1, pp. S48-S65
Open Access | Times Cited: 39
Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial
Conrad‐Amadeus Voltin, Jasmin Mettler, Lutz van Heek, et al.
Clinical Cancer Research (2020) Vol. 27, Iss. 2, pp. 402-407
Open Access | Times Cited: 33
Pitfalls in the Diagnosis of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Variant Patterns, Borderlines and Mimics
Sheren Younes, Rebecca Rojansky, Joshua Menke, et al.
Cancers (2021) Vol. 13, Iss. 12, pp. 3021-3021
Open Access | Times Cited: 31
PET/CT in Hodgkin Lymphoma: An Update
Akram Al‐Ibraheem, Felix M. Mottaghy, Malik E. Juweid
Seminars in Nuclear Medicine (2022) Vol. 53, Iss. 3, pp. 303-319
Closed Access | Times Cited: 22
Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis
Anna Sureda, Astrid Pavlovsky, D. Haidar, et al.
Bone Marrow Transplantation (2025)
Open Access
Rehabilitation in patients with lymphoma: An overview of Systematic Reviews
Bhasker Amatya, Fary Khan, Thomas E. Lew, et al.
Journal of Rehabilitation Medicine (2021) Vol. 53, Iss. 3, pp. jrm00163-jrm00163
Open Access | Times Cited: 25
Pre‐treatment total metabolic tumour volumes in lymphoma: Does quantity matter?
Tarec Christoffer El‐Galaly, Diego Villa, Chan Y. Cheah, et al.
British Journal of Haematology (2022) Vol. 197, Iss. 2, pp. 139-155
Closed Access | Times Cited: 17
A single-armed proof-of-concept study of Lymfit: A personalized, virtual exercise intervention to improve health outcomes in lymphoma survivors in the pandemic
Christopher Angelillo, Wing Lam Tock, Matthew Salaciak, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0275038-e0275038
Open Access | Times Cited: 3
CD38 as theranostic target in oncology
Valentina Bassareo, Jessica Bridoux, Puchowicz Michelle, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Second Malignancies Among Elderly Survivors of Cancer
Ari M. Vanderwalde, Arti Hurria
The Oncologist (2011) Vol. 16, Iss. 11, pp. 1572-1581
Open Access | Times Cited: 36
HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana
Kaelo Moahi, Tlotlo Ralefala, Isaac Nkele, et al.
JCO Global Oncology (2022), Iss. 8
Open Access | Times Cited: 15
Ultrasonography‐guided core‐needle biopsy of lymphadenopathies suspected of lymphoma: Analysis on diagnostic efficacy and safety of 1000 front‐line biopsies in a multicenter Italian study
Marco Picardi, Claudia Giordano, Elena Vigliar, et al.
Hematological Oncology (2023) Vol. 41, Iss. 5, pp. 817-827
Open Access | Times Cited: 8
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study
Amira Marouf, Anne‐Ségolène Cottereau, Salim Kanoun, et al.
Haematologica (2021) Vol. 107, Iss. 7, pp. 1681-1686
Open Access | Times Cited: 18
Baseline 18F-FDG PET/CT Radiomics in Classical Hodgkin’s Lymphoma: The Predictive Role of the Largest and the Hottest Lesions
Elizabeth Katherine Anna Triumbari, Roberto Gatta, Elena Maiolo, et al.
Diagnostics (2023) Vol. 13, Iss. 8, pp. 1391-1391
Open Access | Times Cited: 7
Intracranial Involvement of Systemic Hodgkin Lymphoma: A Case Report and Literature Review
H.W. Lee, Sangjun Ahn, Seung Heon, et al.
Brain Tumor Research and Treatment (2024) Vol. 12, Iss. 1, pp. 63-63
Open Access | Times Cited: 2
Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis
Pier Luigi Zinzani, Robert Chen, Philippe Armand, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2020) Vol. 61, Iss. 4, pp. 950-954
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top